// App-Quantinova.ai

388 : Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors

Researchers

Presenter

  • Johanna Bendell

Principal Investigators

  • Wells Messersmith

  • Drew Rasco

  • Andrea Wang-Gillam

  • Wungki Park

  • Lei Zhou

  • Laura Carter

  • Jean-Marie Bruey

  • Jack Li

  • Beatrice Ferguson

  • Jakob Dupont

  • Marya Chaney

  • Johann De Bono

Medical Centers

  • Sarah Cannon Research Institute, Nashville, TN

  • University of Colorado Denver School of Medicine, Aurora, CO

  • START Center for Cancer Care, San Antonio, TX

  • Washington University School of Medicine, St. Louis, MO

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Gossamer Bio, Inc.,San Diego, CA,USA

  • Merck and Co, Inc., Kenilworth, NJ, USA

  • The ICR and Royal Marsden, London, UK

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Triple-negative breast cancer

  • Solid malignancies

  • Prostate cancer

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Gemcitabine

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved